GRCL - Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy Paxlovid

• China's National Medical Products Administration approved Pfizer's Paxlovid, an oral COVID-19 therapy for adults who have mild-to-moderate COVID-19 and are at high risk of progressing to severe disease. The approval is conditional, based on Pfizer providing additional data.
• Shanghai SciNeuro Pharma and Alamar Pharma of Fremont, CA, formed a drug discovery collaboration that uses Alamar's Attobody platform to discover novel antibodies for neuroscience targets specified by SciNeuro.
• Suzhou Innovent reported that IBI306, the company's recombinant fully-human anti-PCSK-9 mAb, met the primary endpoint of lowering low-density lipoprotein cholesterol in two China registrational trials.
• Moderna announced plans to open subsidiaries in four Asian countries - Hong Kong, Singapore, Taiwan and Malaysia.

For further details see: